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Abstract
Background Sex-specific differences in left ventricular ejection fraction (LVEF) and responses to neurohormonal modulating
therapies are relevant to clinical trials of treatment for heart failure with preserved ejection fraction (HFpEF).
Aims This study aimed to identify the proportion and characteristics of patients presenting with possible or confirmed HFpEF
within the National Echo Database of Australia.
Results A total of 237 046 women (48.1%) and 256 019 men (aged 61.0 ± 18.3 vs. 60.6 ± 17.1 years, respectively)
had sex-specific distributions of LVEF: 94.3% of women had LVEF ≥ 45% (mean LVEF 66.0 ± 8.6%), compared with
87.2% of men (mean LVEF 63.4 ± 8.7%). The presence of structural heart disease (SHD) according to the PARAGON-HF
criteria could be calculated in 93.8% of women and 93.4% of men with an LVEF ≥ 45%. Of these, 64 502 (30.8%) women
and 104 344 (50.0%) of men had left ventricular hypertrophy, and 78 948 (35.3%) and 95 846 (42.9%), respectively,
had left atrial enlargement. As a result, the proportion of women vs. men fulfilling echocardiographic criteria for HFpEF
was very different: 111 497 (53.2%) vs. 146 359 (70.1%). SHD markedly increased with age, associated with a greater
increase in women than men. The same signal was observed in those referred for suspected or previously confirmed
HFpEF.
Conclusions Double the number of men than women had LVEF < 45%, and the distribution of SHD had was highly sex
specific. Left ventricular hypertrophy and left atrial enlargement were more common in men and becoming more frequent
in women with advancing age. The echocardiographic SHD distribution was similar in those referred with suspected or
confirmed HFpEF. The findings are relevant to sex-specific recruitment criteria for future clinical trials.
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Background
In contrast to clear benefits of applying neurohormonal
modulating therapies demonstrated in those with heart
failure (HF) with reduced ejection fraction, ideal treatment
for those with HF with preserved ejection fraction (HFpEF)
remains unclear.1 Because of sex-related differences in HF
with reduced ejection fraction, this inherently means that
more men than women have access to definitive, potentially
life-saving treatment. Recently, composite findings from key
trials, such as TOPCAT2 and PARAGON-HF,3 suggest that
women with more ‘preserved’ left ventricular (LV) function
respond better to such treatment.4 If confirmed, this
observation will undoubtedly increase the pool of overall
treatable cases with HFpEF. It might also redress the
persistent issue of inequitable access to evidence-based
HF therapies based on sex. However, to what extent is
currently unknown.
Aims
Within the real-world patient cohort of the second iteration
of the National Echocardiography Database of Australia
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(NEDA) Study,5 we sought to determine the proportion and
characteristics of those who presented (on their first echocar-
diogram) with potential HFpEF based on an ejection fraction
LVEF ≥ 45% and concurrent evidence of structural heart
disease (SHD).
Methods
As described in greater detail previously,5 NEDA is a very
large, ongoing observational registry that captures individual
echocardiographic reporting data that are robustly linked to
mortality outcomes via the National Death Index of
Australia. It conforms to the highest standards of
observational reporting, has received all relevant ethics
approvals, and adheres to the Declaration of Helsinki. NEDA
is also registered with the Australian New Zealand Clinical
Trials Registry (ACTRN12617001387314). For the purpose of
this report, profiling data on 493 155 individual cases with a
first-reported echocardiogram conducted at 23 different
centres Australia wide (https://www.neda.net.au/
participating-sites/) during the period January 2000 to May
2019 were analysed.
All echocardiographic measurement and report data,
including basic demographic profiling (biological sex and
date of birth) and date of investigation, contained in the
echocardiographic database of participating centres were
collected and remotely transferred into a central database
via a ‘vendor-agnostic’ automated data extraction process.
Following a rigorous data cleaning and linkage process
(including the application of text recognition software to
capture free text reporting), the Master NEDA Database
(v2.0) was finalized.
All individual LVEF values were initially recoded into
five-unit groups, and a total of 446 848 cases with an
LVEF ≥ 45% (90.6%) were identified. For the purpose of this
report, PARAGON-HF Trial criteria3 were applied to
determine the presence of SHD based on current evidence
of (i) LV hypertrophy (LVH), defined as septal or posterior
wall thickness >1.1 cm, and/or (ii) left atrial (LA)
enlargement defined as any of the following: (a) LA width
>3.8 cm, (b) LA length >5.0 cm, (c) LA area >20 cm2, (d)
LA volume >55 mL, and/or (e) LA volume index
>29 mL/m2. With no sex-specific adjustments, as
originally applied, Criteria a–c and d/e were derived from
four-chamber views and the biplane method, respectively.
The overall distribution of cases fulfilling these criteria, with
subgroup analyses of those referred with symptoms
indicative of HF and those with a diagnosis of HF, is
presented on an age and sex-specific basis with no
imputation of missing data. Given the enormous size of
the cohort, unless otherwise indicated, all statistical
comparisons resulted in a P-value <0.001.
Results
The cohort comprised 237 046 women (48.1%) who were
slightly older (61.0 ± 18.3 vs. 60.6 ± 17.1 years) than their
Figure 1 Age distribution of structural heart disease in men and women with a left ventricular ejection fraction ≥45%. The proportion of cases with
(dark bars) and without (light bars) according to age group is shown separately for women (top graph) and men separately (bottom) with equivalent
results for those with heart failure (HF) symptoms or diagnosis also provided (right graphs).
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256 019 male counterparts. The distribution of cases with an
LVEF above and below 45% was highly sex specific. Among
women, there were 13 544 cases (5.7%) with an LVEF < 45%
(mean 33.6 ± 8.6%); those with LVEF ≥ 45% (mean LVEF
66.0 ± 8.6%) were older (68.5 ± 16.4 vs. 60.5 ± 18.4 years),
slightly heavier (body mass index 28.0 ± 7.0 vs.
27.7 ± 7.4 kg/m2), with lower estimated right ventricular
systolic pressures (32.1 ± 10.7 vs. 37.6 ± 12.4 mmHg), and
had less valvular disease (14.0% vs. 37.6%). Among men, there
were more than double presenting with an LVEF < 45%
(32 773–12.8%, mean 32.6 ± 8.9%). The remainder of men
(LVEF 63.4 ± 8.7%) were also older (66.5 ± 14.9 vs.
59.8 ± 17.2 years), had equivalent body mass indices
(28.1 ± 5.5 kg/m2), but with similarly lower estimated right
ventricular systolic pressures (31.9±10.2 vs.37.1±12.1mmHg)
and less valvular disease (13.2% vs. 31.8%).
Overall, 209 706 (93.8%) and 208 656 (93.4%) women and
men with an LVEF ≥ 45%, respectively, had sufficient
echocardiographic measurements to define the presence of
SHD according to the PARAGON-HF criteria. Of these,
64 502 (30.8%) and 78 948 (35.3%) of women fulfilled the
criteria for LVH and LA enlargement. The equivalent
figures among men were much higher, being 104 344
(50.0%) for LVH and 95 846 (42.9%) for LA enlargement,
respectively. Accordingly, the overall proportion of women
(111 497–53.2%) vs. men (146 359–70.1%) fulfilling
echocardiographic criteria for SHD and potential HFpEF was
markedly different. As shown in Figure 1, there was a strong
increase in the prevalence of SHD for those with an
LVEF ≥ 45% in both sexes overall but even stronger in women
than men (rising from 25.4% to 80.3% and from 43.7% to
84.6% in those aged 18–29 to 90+ years, respectively). Be-
cause NEDA does not (yet) capture clinical co-morbidity data
or N-terminal pro-brain natriuretic peptide values, the later
required for recruitment into PARAGON-HF, we also analysed
those referred with suspected or known HF. As also shown in
Figure 1, the proportion of both women (9842/15 215 and
8139/15 215) and men (7740/10 114 and 8064/9752) with
SHD was progressively higher in patients referred for
investigation with HF symptoms and a pre-confirmed diagno-
sis of HFpEF, respectively, noting the same age gradients
being evident.
Conclusions
Using data from a very large echocardiographic repository,
we found that double the number of men than women had
LVEF < 45%. Applying PARAGON-HF criteria for SHD3 identi-
fied many more men than women fulfilling the criteria for
LVH and LA enlargement, particularly with increasing age,
and proportionally more women had a preserved LVEF. This
finding was maintained in patients referred with suspected
or confirmed HF. The SHD criteria resulted in significant sex
differences in LVEF ≥ 45% and is likely to have influenced
the broad pool of cases from which recent trials (such as
PARAGON-HF3 and TOPCAT2) have recruited.4 Rather than
the use of two-dimensional LV linear dimensions, guidelines
recommend the use of indexed LV mass to identify LVH.6 Sim-
ilarly, indexed LA volumes are preferred over linear measure-
ments. The inclusive nature of the defined criteria for SHD in
these trials, as well as the absence of sex-specific criteria, may
possibly have allowed some patients without significant SHD
to be recruited.6 Our finding of sex-specific differences in
LVEF and SHD is clinically important given the need for spe-
cific echocardiographic criteria for future clinical trials, an
increasing focus on finding effective HFpEF treatments, and
evidence that women potentially benefit more than men
from neurohormonal modulating therapy.4
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